Results from the ATTAIN-MAINTAIN trial show that orforglipron pills helped patients keep most of their weight loss after stopping injectable tirzepatide or semaglutide. Participants switching to the daily oral GLP-1 maintained far more weight reduction than those on placebo. The study involved 376…
The trial tested the ability of the oral GLP-1 to sustain prior weight reductions. Participants had already lost weight from long-term injectable use. Results highlighted better retention of those losses with the pill form.
The study enrolled 376 participants located in the US. All had received injectable tirzepatide or semaglutide for more than one year and achieved weight loss during that period. After stopping the injections, they entered the double-blind, randomized trial.
Researchers divided participants into groups receiving either oral orforglipron or placebo. The focus was on weight maintenance over 52 weeks. This design allowed direct comparison of the oral therapy's effects.
Individuals who switched from injectable tirzepatide to oral orforglipron retained 74.7% of their prior weight loss by week 52. In contrast, the placebo group held onto only 49.2% of that loss. This created a treatment difference of about 25.5% in weight reduction.
From week zero to week 52, those on orforglipron experienced an average body weight drop of around 5kg in the tirzepatide cohort. Placebo users regained more weight overall. These figures underscore the pill's role in stabilizing reductions.
For participants discontinuing semaglutide injections, orforglipron led to maintenance of 79.3% of earlier weight loss at week 52. The placebo group managed just 37.6% retention. The estimated treatment difference reached 41.7% after one year.
Average weight change from week zero to 52 was about 1kg loss in the orforglipron semaglutide cohort. This pattern showed even stronger benefits compared to the tirzepatide results. Placebo led to greater regain in this subgroup.
Researchers observed that patients and some clinicians often believe obesity medications can stop after initial weight loss. In reality, stopping intentional weight loss drugs may cause weight cycling and diminish cardiometabolic gains. Continuous therapy helps preserve benefits.
Oral orforglipron appears as a scalable choice worldwide for holding weight steady post-injectable GLP-1 use. The drug is now available in the US and may launch soon in the UK. These factors support broader access to maintenance options.
The full study is Aronne LJ et al. Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial. Nat Med. 2026;10.1038/s41591-026-04386-7.
---
Looking for high-purity research peptides? Browse our catalog for HPLC-verified compounds.
| Compound | Purity | Size | Price |
|---|---|---|---|
| Semaglutide 10mg /product/semaglutide-10mg | ≥98% | 10mg | $49.00 |
| Tirzepatide 10mg /product/tirzepatide-10mg | ≥98% | 10mg | $34.00 |
Browse Full Catalog → /catalog
Peptides referenced: Semaglutide, Tirzepatide, Orforglipron, GLP-1.
Related reading: Survodutide Shows Renal and Metabolic Gains in DKD Mouse Model at ECO 2026, ECO 2026: ATTAIN-MAINTAIN Trial Shows Orforglipron in Sustained Weight Loss, Adults Retain Most Weight Loss After Switching to Foundayo, Oral Orforglipron Maintains Weight Loss After Injectables in ATTAIN-MAINTAIN Trial.